Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.985 USD | +3.28% | -4.48% | -19.87% |
10/05 | HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating | MT |
09/05 | 89bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.87% | 86Cr | |
+4.81% | 11TCr | |
+11.01% | 11TCr | |
-12.28% | 2.23TCr | |
-3.84% | 2.19TCr | |
-6.03% | 1.86TCr | |
-36.52% | 1.81TCr | |
-9.92% | 1.7TCr | |
+3.04% | 1.37TCr | |
+36.28% | 1.24TCr |
- Stock Market
- Equities
- ETNB Stock
- News 89bio, Inc.
- 89bio Says Liver Disease Phase 2 Trial of Pegozafermin Showed 'Clinically Meaningful' Improvements in Biomarkers